Mutant Amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine

被引：15

作者：

Cao, Chuanhai ^{[1
,2
]}

Lin, Xiaoyang ^{[1
,2
]}

Zhang, Chi ^{[1
,2
]}

Wahi, Monika M. ^{[1
,2
,3
]}

Wefes, Inge ^{[4
]}

Arendash, Gary ^{[1
,2
,5
]}

Potter, Huntington ^{[1
,2
,4
]}

机构：

[1] Johnnie B Byrd Sr Alzheimers Ctr, Tampa, FL 33613 USA

[2] Res Inst, Tampa, FL 33613 USA

[3] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL 33612 USA

[4] Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA

[5] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33612 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2008年 / 200卷 / 1-2期

关键词：

Dendritic cells; Vaccines; Amyloid beta-peptide; Alzheimer's disease; Epitopes; Th1; Cells; Th2; cells; Inflammation;

D O I：

10.1016/j.jneuroim.2008.05.017

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vaccines using bone marrow-derived dendritic cells (DCs) sensitized to A beta 1-42 peptide and other mutant peptides were tested on BALB/c and APP(sw) transgenic mice. Wild type A beta 1-42-sensitized DC vaccine (DCSV) produced no response, but all peptides with a T-cell epitope mutation induced antibody responses without inflammation. DCSV with A beta 1-25 peptide with mutated T-cell epitope failed to induce antibody response, while DCSV with A beta 1-35 with mutated T-cell epitope produced a strong antibody response. The entire T-cell epitope is required in a DC vaccine to induce antibody response. DCSV with A beta peptide carrying the entire mutant T-cell epitope may be an appropriate vaccine against AD. (c) 2008 Elsevier B.V. All rights reserved.

引用

页码：1 / 10

页数：10

共 48 条

[1] *ALZH ASS, 2007, ALZH DIS PREV RAT RI
[2] A dendritic cell-based vaccine for treating HIV infection: background and preliminary results
Andrieu, J. M.
Lu, W.
[J]. JOURNAL OF INTERNAL MEDICINE, 2007, 261 (02) : 123 - 131
[3] Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA
Barrou, B
Benoît, GR
Ouldkaci, M
Cussenot, O
Salcedo, M
Agrawal, S
Massicard, SV
Bercovici, N
Ericson, ML
Thiounn, N
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (05) : 453 - 460
[4] Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, AJ
Bullock, R
Jones, RW
Wilkinson, D
Paterson, KR
Jenkins, L
Millais, SB
Donoghue, S
[J]. NEUROLOGY, 2005, 64 (01) : 94 - 101
[5] CIARAMELLA A, 2007, NEUROBIOL AGING
[6] B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice
Cohen, S
Haimovich, J
Hollander, N
[J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) : 461 - 466
[7] Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid
Cribbs, DH
Ghochikyan, A
Vasilevko, V
Tran, M
Petrushina, I
Sadzikava, N
Babikyan, D
Kesslak, P
Kieber-Emmons, T
Cotman, CW
Agadjanyan, MG
[J]. INTERNATIONAL IMMUNOLOGY, 2003, 15 (04) : 505 - 514
[8] Flemish and Dutch mutations in amyloid β precursor protein have different effects on amyloid β secretion
De Jonghe, C
Zehr, C
Yager, D
Prada, CM
Younkin, S
Hendriks, L
Van Broeckhoven, C
Eckman, CB
[J]. NEUROBIOLOGY OF DISEASE, 1998, 5 (04) : 281 - 286
[9] Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice
Ethell, Douglas W.
Shippy, Daniel
Cao, Chuanhai
Cracchiolo, Jennifer R.
Runfeldt, Melissa
Blake, Brett
Arendash, Gary W.
[J]. NEUROBIOLOGY OF DISEASE, 2006, 23 (02) : 351 - 361
[10] Hematopoietic growth factors, dendritic cell biology, and vaccine therapy of cancer
Fay, JW
[J]. CURRENT OPINION IN HEMATOLOGY, 2002, 9 (03) : 202 - 206

← 1 2 3 4 5 →